FM
IRWD icon

Fondren Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Fondren Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-40,000
Closed -$438K – 82
2019
Q2 		$438K Buy
+40,000
New +$448K 0.42% 53

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fondren Management's IRWD Position: Q3 2019 in Review

Fondren Management sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2019, closing a stake of 40,000 shares — an estimated $438K sold.

Fondren Management first reported a position in IRWD in Q2 2019 and held it in 1 quarter. The position peaked at $438K in Q2 2019. 164 funds tracked by Wall St. Rank hold IRWD as of Q3 2019.

  • Fondren Management reported no remaining Ironwood Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Fondren Management sold 40,000 Ironwood Pharmaceuticals shares in Q3 2019, an estimated $438K.
  • Fondren Management first reported a position in Ironwood Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Fondren Management's Ironwood Pharmaceuticals position peaked at $438K in Q2 2019.
  • 164 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2019.

Based on Fondren Management's 13F filing for Q3 2019, filed 14 Nov 2019.